Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

2.

Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone.

Persky DO, Dornan D, Goldman BH, Braziel RM, Fisher RI, Leblanc M, Maloney DG, Press OW, Miller TP, Rimsza LM.

Haematologica. 2012 Jun;97(6):937-42. doi: 10.3324/haematol.2011.050419. Epub 2012 Jan 22.

3.
4.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
5.

Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35/98).

Lee CS, Ashton-Key M, Cogliatti S, Rondeau S, Schmitz SF, Ghielmini M, Cragg MS, Johnson P.

Br J Haematol. 2015 Jan;168(1):145-8. doi: 10.1111/bjh.13071. Epub 2014 Aug 21. No abstract available.

PMID:
25142001
6.

Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.

Keating GM.

Drugs. 2010 Jul 30;70(11):1445-76. doi: 10.2165/11201110-000000000-00000. Review.

PMID:
20614951
8.

Rituximab for follicular non-Hodgkin lymphoma.

Gajraj E, Chung H, Longson C, Stevens A.

Lancet Oncol. 2008 Apr;9(4):320-1. doi: 10.1016/S1470-2045(08)70036-6. Epub 2008 Mar 3. No abstract available.

PMID:
18405852
9.

Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.

Papaioannou D, Rafia R, Rathbone J, Stevenson M, Buckley Woods H, Stevens J.

Health Technol Assess. 2012;16(37):1-253, iii-iv. Review.

10.

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, Neri TM, Ardizzoni A.

J Clin Oncol. 2008 Apr 10;26(11):1789-96. doi: 10.1200/JCO.2007.14.8957. Epub 2008 Mar 17.

11.

Diagnosis and treatment of follicular lymphoma.

Hitz F, Ketterer N, Lohri A, Mey U, Pederiva S, Renner C, Taverna C, Hartmann A, Yeow K, Bodis S, Zucca E.

Swiss Med Wkly. 2011 Aug 4;141:w13247. doi: 10.4414/smw.2011.13247. Review.

12.

[Standard therapy and research questions in follicular lymphoma].

Ishizawa K.

Rinsho Ketsueki. 2012 Oct;53(10):1624-33. Review. Japanese. No abstract available.

PMID:
23037735
13.

Effect of FCGR2A and FCGR3A variants on CLL outcome.

Dornan D, Spleiss O, Yeh RF, Duchateau-Nguyen G, Dufour A, Zhi J, Robak T, Moiseev SI, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, Catalano J, Afanasiev BV, Larratt L, Rossiev VA, Bence-Bruckler I, Geisler CH, Montillo M, Wenger MK, Weisser M.

Blood. 2010 Nov 18;116(20):4212-22. doi: 10.1182/blood-2010-03-272765. Epub 2010 Aug 12.

14.

Rituximab: as first-line maintenance therapy following rituximab-containing therapy for follicular lymphoma.

Croxtall JD.

Drugs. 2011 May 7;71(7):885-95. doi: 10.2165/11206720-000000000-00000. Review.

PMID:
21568365
15.
16.

Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, Lamy A, Penault-Llorca F, Frébourg T, Michel P, Sabourin JC, Boissière-Michot F.

J Clin Oncol. 2009 Mar 1;27(7):1122-9. doi: 10.1200/JCO.2008.18.0463. Epub 2009 Jan 21.

17.

FcγRIIIA receptor genotype does not influence an outcome in patients with follicular lymphoma treated with risk-adapted immunochemotherapy.

Prochazka V, Papajik T, Gazdova J, Divoka M, Rozmanova S, Faber E, Raida L, Kucerova L, Langova K, Jarosova M, Indrak K.

Neoplasma. 2011;58(3):263-70.

PMID:
21395368
18.

Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study.

Sweetenham JW, Goldman B, LeBlanc ML, Cook JR, Tubbs RR, Press OW, Maloney DG, Fisher RI, Rimsza LM, Braziel RM, Hsi ED.

Ann Oncol. 2010 Jun;21(6):1196-202. doi: 10.1093/annonc/mdp460. Epub 2009 Oct 29.

19.

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma.

Schulz H, Bohlius J, Skoetz N, Trelle S, Kober T, Reiser M, Dreyling M, Herold M, Schwarzer G, Hallek M, Engert A.

Cochrane Database Syst Rev. 2007 Oct 17;(4):CD003805. Review.

PMID:
17943799
20.

[A case of follicular lymphoma of the duodenum treated with the combined therapy of anti-CD20 antibody and chemotherapy].

Isogai K, Yamamoto E, Yamaoka S, Tarasawa I, Murakami R, Morimoto I, Obata T, Mori M, Endo T, Imai K.

Nihon Shokakibyo Gakkai Zasshi. 2006 Mar;103(3):301-9. Review. Japanese. No abstract available.

PMID:
16688961
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk